| Literature DB >> 23593155 |
Diana Espadinha1, Nuno A Faria, Maria Miragaia, Luís Marques Lito, José Melo-Cristino, Hermínia de Lencastre.
Abstract
According to the EARS-Net surveillance data, Portugal has the highest prevalence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) in Europe, but the information on MRSA in the community is very scarce and the links between the hospital and community are not known. In this study we aimed to understand the events associated to the recent sharp increase in MRSA frequency in Portugal and to evaluate how this has shaped MRSA epidemiology in the community. With this purpose, 180 nosocomial MRSA isolates recovered from infection in two time periods and 14 MRSA isolates recovered from 89 samples of skin and soft tissue infections (SSTI) were analyzed by pulsed-field gel electrophoresis (PFGE), staphylococcal chromosome cassette mec (SCCmec) typing, spa typing and multilocus sequence typing (MLST). All isolates were also screened for the presence of Panton Valentine leukocidin (PVL) and arginine catabolic mobile element (ACME) by PCR. The results showed that ST22-IVh, accounting for 72% of the nosocomial isolates, was the major clone circulating in the hospital in 2010, having replaced two previous dominant clones in 1993, the Iberian (ST247-I) and Portuguese (ST239-III variant) clones. Moreover in 2010, three clones belonging to CC5 (ST105-II, ST125-IVc and ST5-IVc) accounted for 20% of the isolates and may represent the beginning of new waves of MRSA in this hospital. Interestingly, more than half of the MRSA isolates (8/14) causing SSTI in people attending healthcare centers in Portugal belonged to the most predominant clones found in the hospital, namely ST22-IVh (n = 4), ST5-IVc (n = 2) and ST105-II (n = 1). Other clones found included ST5-V (n = 6) and ST8-VI (n = 1). None of the MRSA isolates carried PVL and only five isolates (ST5-V-t179) carried ACME type II. The emergence and spread of EMRSA-15 may be associated to the observed increase in MRSA frequency in the hospital and the consequent spillover of MRSA into the community.Entities:
Mesh:
Year: 2013 PMID: 23593155 PMCID: PMC3617237 DOI: 10.1371/journal.pone.0059960
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Main characteristics of nosocomial MRSA isolates collected in 1993 and 2010.
| Year | PFGE type, no. isolates (%) | SCC |
| ST (CC) | Resistance Profile |
|
| |||||
| M, 39 (72.2%) | I | t008/t051 | 247 (8) | OX-ERY-CLI-CIP-TE-CN (8) | |
| OX-ERY-CIP-TE-RD-CN (8) | |||||
| OX-ERY-CIP-TE-CN (7) | |||||
| OX-ERY-CLI-CIP-TE-RD-CN (4) | |||||
| OX-ERY-CIP-QD-TE-CN (3) | |||||
| OX-ERY-CLI-CIP-QD-TE-RD-CN (1) | |||||
| OX-ERY-CLI-CIP-QD-TE-CN (1) | |||||
| OX-ERY-SXT-TE-CN (1) | |||||
| OX-ERY-CIP-QD-TE-RD-CN (1) | |||||
| OX-ERY-CIP-QD-TE-RD (1) | |||||
| OX-ERY-CIP-SXT-TE-CN (1) | |||||
| OX-ERY-CIP-SXT-TE (1) | |||||
| OX-ERY-CIP-TE-RD (1) | |||||
| OX-ERY-CIP-RD-CN (1) | |||||
| N, 12 (22.2%) | III variant | t421 | 239 (8) | OX-ERY-CIP-QD-SXT-TE-CN (4) | |
| OX-ERY-SXT-TE-CN (2) | |||||
| OX-ERY-TE-RD-CN (2) | |||||
| OX-CIP-SXT-TE-CN (1) | |||||
| OX-ERY-CIP-SXT-TE (1) | |||||
| OX-ERY-CIP-QD-SXT-TE (1) | |||||
| OX-ERY-QD-SXT-TE-CN (1) | |||||
|
| |||||
| O, 3 (5.6%) | III variant | t421 | 239 (8) | OX-ERY-CIP-SXT-TE-CN (2) | |
| OX-ERY-CIP-TE-RD-CN (1) | |||||
| K, 129 (71.7%) | IVh (129) | t2357/t910/t025/t032/t1467/t1302 | 22 (22) | OX-ERY-CIP (94) | |
| OX-CIP (22) | |||||
| OX-ERY-CLI-CIP (4) | |||||
| OX-ERY-CIP-FD (3) | |||||
| OX-ERY-CLI-CIP-QD (2) | |||||
| OX-ERY-CIP-RD (1) | |||||
| OX-ERY-CIP-TE (1) | |||||
| OX-ERY-CIP-SXT (1) | |||||
| ERY-CIP (1) | |||||
| I, 38 (21.1%) | II (30) | t002 | 105 (5) | OX-ERY-CIP (16) | |
| OX-ERY-CLI-CIP (8) | |||||
| OX-ERY-CIP-FD (3) | |||||
| OX-ERY-CLI-CIP-FD (2) | |||||
| OX-ERY-CIP-RD (1) | |||||
| IVc (7) | t067/t002 | 125 (5) | OX-CIP (4) | ||
| OX-ERY-CIP (2) | |||||
| OX-ERY-CLI-CIP-QD (1) | |||||
| IVc (1) | t535 | 5 (5) | OX-CIP-RD (1) | ||
| F, 5 (2.8%) | III (3) | t037 | 2246 (8) | OX-ERY-CLI-CIP-SXT-TE-RD-CN (3) | |
| IVa (2) | t127 | 1 (15) | OX-ERY-TE (2) | ||
| B, 4 (2.2%) | II (4) | t018 | 36 (30) | OX-ERY-CLI-CIP (4) | |
| C, 2 (1.1%) | IVc (1) | t008 | 8 (8) | OX-ERY-CIP (1) | |
| VI (1) | t024 | 8 (8) | OX-FD (1) | ||
| E, 2 (1.1%) | II (2) | t002 | 105 (5) | OX-ERY-CIP (2) | |
One isolate with SCCmec type I variant: presence of mec complex class B and ccrAB type 1 was confirmed in simplex PCR;
No amplification could be retrieved from SCCmec type III J1 locus (primer RIF5 F10/RIF5 R13). The presence of mec complex class A and ccrAB type 3 was confirmed in simplex PCR;
spa typing and MLST were only performed on representative isolates of each PFGE type-SCCmec association;
OX, oxacillin; E, erythromycin; CLI, clindamycin; LZD, linezolid; CIP, ciprofloxacin; QD, quinupristin-dalfopristin; SXT, sulfamethoxazole-trimethoprim; TE, tetracycline; FD, fusidic acid; RD, rifampicin; VAN, vancomycin; CN, gentamicin.
Main characteristics of the 14 MRSA isolates collected in the healthcare centers in 2010/2011.
| PFGE type, no.isolates (%) | SCC |
| ST (CC) | PVL | ACME(no. isolates) | Resistance Profile |
| I, 6 (43%) | IVc (2) | t535 | 5 (5) | – | – | CIP-FD (1) |
| OX-ERY-CIP-QD-FD (1) | ||||||
| V (3) | t179 | 5 (5) | – |
| CIP-CN (2) | |
| t442 | 5 (5) | – | – | CIP-SXT-TE-CN (1) | ||
| II (1) | t002 | 105 (5) | – | – | OX-ERY-CIP (1) | |
| P, 3 (21%) | V | t179 | 5 (5) | – |
| CIP-FD-CN (1) |
| ERY-CIP-FD-CN (1) | ||||||
| ERY-CIP-QD-FD-CN (1) | ||||||
| K, 4 (29%) | IVh (4) | t032/t5888/t2357 | 22 (22) | – | – | OX-ERY-CIP (2) |
| OX-CIP (1) | ||||||
| OX-ERY-CLI-CIP-QD (1) | ||||||
| Q, 1 (7%) | VI (1) | t008 | 8 (8) | – | – | CIP-FD (1) |
Isolates carry the ccrAB1, ccrC and mec complex C2. SCCmec type was confirmed by long-range PCR;
spa typing and MLST were only performed on representative isolates of each PFGE type-SCCmec association.
OX, oxacillin; E, erythromycin; CLI, clindamycin; LZD, linezolid; CIP, ciprofloxacin; QD, quinupristin-dalfopristin; SXT, sulfamethoxazole-trimethoprim; TE, tetracycline; FD, fusidic acid; RD, rifampicin; VAN, vancomycin; CN, gentamicin.
Figure 1MRSA population structure in the hospital and community in Portugal.
Schematic representation of the MRSA population structure in the hospital and community settings and the possible dissemination of hospital clones into the community.